| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
18,907 |
14,788 |
$3.91M |
| J0178 |
Injection, aflibercept, 1 mg |
1,961 |
1,362 |
$2.51M |
| J2778 |
Injection, ranibizumab, 0.1 mg |
3,398 |
2,497 |
$2.30M |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
1,871 |
1,155 |
$1.28M |
| 92134 |
|
23,124 |
22,382 |
$551K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
8,450 |
8,291 |
$397K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
8,314 |
8,144 |
$363K |
| J9035 |
Injection, bevacizumab, 10 mg |
2,048 |
1,337 |
$145K |
| 92226 |
|
5,142 |
3,060 |
$112K |
| 92250 |
|
2,718 |
2,656 |
$97K |
| 92235 |
|
731 |
717 |
$62K |
| J3490 |
Unclassified drugs |
25 |
17 |
$21K |
| 92202 |
|
1,456 |
1,435 |
$16K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
241 |
230 |
$11K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
141 |
140 |
$8K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
95 |
91 |
$7K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
163 |
161 |
$7K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
117 |
115 |
$6K |
| 92201 |
|
452 |
439 |
$5K |
| 92225 |
|
24 |
12 |
$1K |
| 76512 |
|
15 |
12 |
$946.87 |
| J7999 |
Compounded drug, not otherwise classified |
70 |
70 |
$0.00 |